Drug Profile
Solriamfetol - Jazz Pharmaceuticals/SK Biopharmaceuticals
Alternative Names: ADX-N05; ARL-N05; JZP-110; SKL-N05; SUNOSI; SunosiLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator SK Holdings
- Developer Axsome Therapeutics; Jazz Pharmaceuticals plc; SK biopharmaceuticals
- Class Antidepressants; Carbamates; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypersomnia
- Phase III Attention-deficit hyperactivity disorder; Major depressive disorder
- Phase II Binge-eating disorder; Circadian rhythm sleep disorders
- Discontinued Depressive disorders